Genting Sunyao Announces First Approval of Trodelvy® in Singapore for Second-Line Treatment of Metastatic Triple-Negative Breast Cancer

"We are very excited about the first approval of Trodelvy in the Asia-Pacific region," said Dr.

Shi Yang, Chief Medical Officer of Oncology at Genting Sunyao, said: “In Singapore, triple-negative breast cancer accounts for approximately 15-20% of all breast cancer cases, and breast cancer is the leading cause of cancer death among women in the country

In addition to Singapore, the relevant regulatory agencies in Greater China and South Korea have accepted relevant review applications for Trodelvy for the treatment of unresectable patients who have received at least two prior systemic therapies, at least one of which is for metastatic disease.

• In May 2021 , the China National Medical Products Administration accepted Trodelvy's biological product marketing authorization application and granted priority review
  
  

  Triple-negative breast cancer is a highly aggressive form of breast cancer, accounting for approximately 15% of all breast cancer types worldwide

  
  

  About Trodelvy (goxatuzumab)

  Trodelvy is a first-in-class antibody and topoisomerase 1 inhibitor antibody-drug conjugate that targets the TROP-2 receptor, an antibody-drug conjugate in many epithelial cancers, including metastatic triple-negative breast cancer and metastatic urothelial carcinoma (UC)), where high expression is associated with poor survival and recurrence

  
  

  According to the license introduction agreement signed with Gilead Sciences, Genting Xinyao has the exclusive rights to develop, register and commercialize all cancer indications of goxatuzumab in Greater China, South Korea and some Southeast Asian countries

  
  

  About Genting Sunrise

  Genting Xinyao is a biopharmaceutical company focused on the development and commercialization of innovative drugs, dedicated to meeting the unmet medical needs of the Asian market